Spackman to be the sleeper hit of financial reporting seasons ahead

SINGAPORE (May 16): RHB is maintaining its “buy” call on Spackman Entertainment Group with a target price of 27 cents, while noting that the stock is currently trading at a much lower valuation versus local peers and has a positive outlook.

To recap, the group on Monday announced 1Q earnings of $7.6 million, reversing from its net loss position in the same quarter a year ago after recognising earnings from its blockbuster movie, Master, as well as a US$3 million gain from the disposal of its Spackman Media Group (SMG) shares in relation to its latest acquisition.

Spackman’s latest acquisition seals the deal for a ‘superb’ 1Q17

SINGAPORE (April 6): RHB Research is maintaining its “buy” call on Spackman Entertainment following its recent acquisition of Frame Pictures, a Korean equipment business, for $1.12 million and 0.5 million shares of its associate, Spackman Media Group (SMG).

Coming soon to a screen near you: A spike in this stock’s 1Q earnings

SINGAPORE (Jan 9): RHB is certain that profits from Master, the latest South Korean crime-action blockbuster to hit the silver screens, will be yielding Spackman Entertainment Group “superb” 1Q17F earnings.

(See also: Spackman breaks even with movie Master)

Spackman breaks even with movie Master

SINGAPORE (Dec 29): Spackman Entertainment Group says its crime-action thriller Master produced by subsidiary Zip Cinema surpassed the film’s breakeven point within eight days of its official wide release on Dec 21.

As of Wednesday, Master has recorded total admissions of 3.8 million with gross box office revenue of US$25.3 million ($37 million), according to latest stats from the Korean Film Council.

Say ‘Annyeong-Haseyo’ to the Hallyu star of stocks

SINGAPORE (Oct 13): RHB is initiating coverage on South Korean move producer Spackman Entertainment Group with a “buy” recommendation and price target of 22 cents, noting the group is “probably in the best health since its IPO” in mid-2014 while presently trading at a significant discount to peers.

In a Thursday report, analyst Jarick Seet says Spackman is “primed for a strong turnaround”, especially given a strong interest of Chinese firms in South Korean content providers in the last five years.

Medical marvel

SINGAPORE (March 10): Louis Phee is no stranger to failure. In the process of developing the Master and Slave Transluminal Endoscopic Robot, or MASTER, he encountered countless failed attempts from which he learnt not to be discouraged. His persistence paid off when the MASTER successfully performed its first-in-man trials in India and Hong Kong in 2011, during which cancerous stomach tumours from five patients were extracted through their oesophageal passage.

Be informed of the stories that matter